Synmosa Biopharma (4114) — Cash Flow-to-Debt Ratio
Synmosa Biopharma (4114) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of NT$185.72 Million could theoretically repay 0% of its total liabilities (NT$3.89 Billion) in one year. Explore Synmosa Biopharma long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Synmosa Biopharma Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Synmosa Biopharma across 11 annual periods. Also explore balance sheet size of Synmosa Biopharma for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Synmosa Biopharma (2015–2025)
Year-by-year debt coverage analysis for Synmosa Biopharma. For market capitalisation and broader financial context, see Synmosa Biopharma stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | NT$411.57 Million | NT$3.89 Billion | ▼ -47.0% |
| 2024 | 0.20x | NT$780.62 Million | NT$3.91 Billion | ▲ +41.6% |
| 2023 | 0.14x | NT$511.93 Million | NT$3.63 Billion | ▲ +2.0% |
| 2022 | 0.14x | NT$630.25 Million | NT$4.55 Billion | ▲ +31.5% |
| 2021 | 0.11x | NT$444.29 Million | NT$4.22 Billion | ▲ +83.0% |
| 2020 | 0.06x | NT$254.40 Million | NT$4.42 Billion | ▲ +602.0% |
| 2019 | -0.01x | NT$-44.88 Million | NT$3.92 Billion | ▼ -319.1% |
| 2018 | 0.01x | NT$16.00 Million | NT$3.06 Billion | ▲ +456.2% |
| 2017 | 0.00x | NT$-5.19 Million | NT$3.54 Billion | ▼ -101.5% |
| 2016 | 0.10x | NT$236.48 Million | NT$2.44 Billion | ▲ +549.1% |
| 2015 | 0.01x | NT$23.60 Million | NT$1.58 Billion | — |